Evidence map›Paper›PMID 36965085›Full record

ArticleCancer medicine2023

Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands.

Tessa M Schurink-van 't Klooster, Albert G Siebers, Joske Hoes, Folkert J van Kemenade, Johannes Berkhof, Johannes A Bogaards, Hester E de Melker

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Tessa M Schurink-van 't KloosterDepartment National Immunisation Programme, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.ORCID 0000-0002-7702-9288
Albert G SiebersPALGA, Houten, The Netherlands.
Joske HoesDepartment National Immunisation Programme, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Folkert J van KemenadeDepartment of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Johannes BerkhofDepartment of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Johannes A BogaardsDepartment National Immunisation Programme, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Hester E de MelkerDepartment National Immunisation Programme, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
National Institute for Public Health and the Environment · NLAmsterdam University Medical Centers · NLErasmus MC · NLKoninklijke Nederlandse Maatschappij voor Diergeneeskunde · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe first HPV-vaccine eligible cohorts in the Netherlands will enter the cervical screening program in 2023. However, a substantial number of young women already have had a cervical sample taken before entry into the regular screening program. This study was initiated to explore early effects of HPV vaccination on detection of cytological abnormalities in cervical samples of women younger than the screening age.

methodsResults of cervical samples were obtained from the Dutch National Pathology Databank (PALGA) and were linked to the women's HPV vaccination status from the national vaccination registry (Praeventis) (N = 42,171). Occurrence of low-grade and high-grade squamous intraepithelial lesions or worse (LSIL and HSIL+) and high-risk HPV positive tests (hrHPV) in the first cervical sample were compared between vaccinated and unvaccinated women by multivariable logistic regression analysis, corrected for age at cervical sampling and age of vaccination (12/13 years, ≥ = 14 years).

resultsFor fully vaccinated women (three- or two-dose schedule), statistically significant reductions were seen for all outcomes compared to unvaccinated women (hrHPV: adjusted OR, 0.70, 95% CI, 0.63-0.79; LSIL: 0.70, 0.61-0.80; HSIL+: 0.39, 0.30-0.51).

conclusionsBy linking nation-wide registries on pathology and vaccination, we show significant beneficial early effects of HPV-vaccination on LSIL, HSIL+, CIN3/AIS/carcinoma and hrHPV detection in young women upto 24 years of age who have a cervical sample taken before entry into the cervical cancer screening program.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesSquamous Intraepithelial Lesions of the CervixUterine Cervical DysplasiaUterine Cervical NeoplasmsChildEarly Detection of CancerFemaleHuman Papillomavirus VirusesHumansNetherlandsPapillomaviridaeVaccinationPapillomavirus Vaccinesbivalent HPV-vaccinecytological cervical abnormalitieshigh-grade cervical lesionshigh-risk HPVHSILhuman papillomaviruslow-grade cervical lesionsLSIL

Identifiers

PMID36965085
PMCPMC10242855
OpenAlexW4360938462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.